Prothena CORP Public LTD CO Form 4 insider transactions

Director Helen Kim acquired 15,000 stock options in Prothena Corp on May 15, 2024, according to a Form 4 filing.

Director Lars Ekman reports acquisition of 15,000 stock options in Prothena Corp on May 15, 2024.

William H. Dunn Jr., a director of Prothena Corp, reports the acquisition of stock options for 15,000 ordinary shares.

Director Shane Cooke acquired 15,000 stock options in Prothena Corp on May 15, 2024.

Director Richard T. Collier acquired 15,000 stock options in Prothena Corp Public Ltd Co on May 15, 2024, at an exercise price of $22.39.

Director Paula K. Cobb acquired 15,000 stock options in Prothena Corp Public Ltd Co on May 15, 2024, exercisable at $22.39.

David A. Ford, Chief People Officer of Prothena Corp Public Ltd Co, acquired 85,000 stock options on March 1, 2024, according to a Form 4 filing with the SEC.

Wagner M. Zago, Chief Scientific Officer of Prothena Corp Public Ltd Co, acquired 85,000 stock options on February 27, 2024, according to a Form 4 filing.

Karin L. Walker, Chief Accounting Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options for 54,000 ordinary shares.

Brandon S. Smith, Chief Operating Officer of Prothena Corp Public Ltd Co, reports the acquisition of 85,000 stock options.

Tran Nguyen, Chief Strategy Officer and CFO of Prothena Corp Public LTD CO, acquired stock options for 85,000 ordinary shares on February 27, 2024.

Michael J. Malecek, Chief Legal Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options.

Gene G. Kinney, President and CEO of Prothena Corp, was granted 307,000 stock options on February 27, 2024.

Carol D. Karp, Chief Regulatory Officer of Prothena Corp Public Ltd Co, acquired 85,000 stock options on February 27, 2024, according to a Form 4 filing with the SEC.

Hideki Garren, Chief Medical Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options for 85,000 ordinary shares.